Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus.
Michael S KellyEmily M ScopellitiKaylee E GoodsonChing Mann Anne LoHuelena X NguyenBarbara SimonPublished in: Diabetes, obesity & metabolism (2024)
In a real-world population of US patients with T2DM, tirzepatide was associated with clinically and statistically significant reductions in A1C and body weight. Greater reductions in both A1C and body weight were observed among patients who were GLP1-RA naïve compared to patients switched from GLP1-RA to tirzepatide.